RCT: Sublingual dexmedetomidine reduces mild to moderate acute agitation in patients with bipolar disorder.

Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Sublingual Dexmedetomidine as a Potential New Treatment for Agitation – JAMA (free for a limited period)

Commentary on Twitter

Randomized clinical trial found sublingual #dexmedetomidine at a dose of 180 μg or 120 μg reduced mild to moderate agitation in patients with #bipolar disorder. https://t.co/1VK2e15F7s pic.twitter.com/0oHw6eVMIP

— JAMA (@JAMA_current) February 22, 2022